Pregled bibliografske jedinice broj: 889969
Epilepsy and pregnancy - which antiepileptic drug should we choose?
Epilepsy and pregnancy - which antiepileptic drug should we choose? // Neurologia / Korczyn, Amos (ur.).
Atena: Hellenic Neurological Society, 2017. str. 16-16 (pozvano predavanje, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 889969 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Epilepsy and pregnancy - which antiepileptic drug should we choose?
Autori
Petelin Gadze, Zeljka
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Neurologia
/ Korczyn, Amos - Atena : Hellenic Neurological Society, 2017, 16-16
Skup
11th World Congress on Controversies in Neurology (CONy)
Mjesto i datum
Atena, Grčka, 23.03.2017. - 26.03.2017
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
epilepsy, pregnancy, treatment
Sažetak
Women with epilepsy have a slightly higher risk for some pregnancy and birth complications and require increased surveillance during pregnancy. Although two of three women with epilepsy remain seizure free throughout pregnancy, antiepileptic drugs (AEDs) dosages may need to be adjusted and therapeutic drug monitoring should be performed, at least every 4 weeks. Due to pharmacokinetic changes during pregnancy, the most pronounced decline in serum concentrations is seen for AEDs eliminated by glucuronidation, in particular lamotrigine (LTG). Consequently, the risks for uncontrolled seizures during pregnancy need to be balanced against potential teratogenic effects of AEDs. AED pregnancy registries continue to confirm that valproate (VPA) poses a significantly increased dose-dependent risk of structural and cognitive teratogenesis, ranging from 5.6% (<750mg/day) to 24.2% (>1500mg/day). Phenytoin (PHT), phenobarbital (PB), and topiramate (TPM) likely confer an intermediate risk and LTG, oxcarbazepine (OXC), and levetiracetam (LEV) are associated with a relatively low risk of congenital malformations. Accordingly, women with epilepsy should be treated with a low-dose monotherapy during pregnancy and VPA should be avoided. Supplementary folic acid (5 mg daily dose) is recommended, because this lowers the risk of cognitive teratogenicity. Third-trimester vitamin K supplementation has been suggested for women taking enzyme-inducing AEDs (eg. CBZ, PHT, PB), based on a concern for increased risk of intracranial neonatal haemorrhage. Experiences of the Referral Centre for Epilepsy of the Ministry of Health of the Republic of Croatia in treating pregnant women with epilepsy will also be presented.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Željka Petelin Gadže
(autor)